Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (scFv4-Ig) (FVTIG-157)

Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (scFv4-Ig) is an appended IgG format, which includes four scFv moieties at the N-termini of the constant regions. It is a bivalent homodimer, in which one anti-EGFR scFv is fused to the CH1 domain of a heavy chain and another anti-IGF1R scFv to the CL domain of a light chain, or vice versa. The resulting leads to 2+2 antigen-binding valency. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer therapy.

Datasheet INQUIRY

Specifications

Targets

EGFR & IGF1R

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer

Targets

Target 1

EGFR

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Target 2

IGF1R

Gene ID

3480

UniProt ID

P08069

Alternative Names

IGF1R; insulin-like growth factor 1 receptor; IGFR; CD221; IGFIR; JTK13; IGF-I receptor; soluble IGF1R variant 1; soluble IGF1R variant 2; insulin-like growth factor I receptor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (scFv4-Ig) (FVTIG-157). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (scFv4-Ig) (CAT#: FVTIG-157)

Specifications

Targets

Customer Reviews and Q&As